List of first, second and third line treatments for advanced non-small cell lung cancer Drug treatment for advanced non-small cell lung cancer lung cancer includes chemotherapy and molecular targeted therapy. Chemotherapy is divided into palliative chemotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy, which should be strictly mastered as indications for treatment and carried out under the leadership of medical oncologists. Chemotherapy should fully consider the patient’s condition and physical status, assess the patient’s possible benefit and ability to tolerate treatment, evaluate the efficacy in a timely manner, closely monitor and effectively prevent and treat adverse reactions. The indications for chemotherapy are: Eastern Cooperative Oncology Group (ECOG) physical status (PS) score ≤ 2, important organ function tolerant to chemotherapy, and for chemotherapy in SCLC, the PS score can be relaxed to 3. First-line drug therapy The platinum-containing two-drug regimen is the standard first-line chemotherapy regimen, which can be combined with vascular endothelial inhibitors on top of chemotherapy. patients with EGFR gene-sensitive mutations or ALK fusion gene-positive patients can be targeted with targeted drug therapy. Maintenance therapy is an option for patients who have achieved disease control with first-line therapy. Second-line drug therapy Second-line therapy options include doxorubicin, pemetrexed and EGFR-TKI. Patients with EGFR gene-sensitive mutations who are not treated with EGFR-TKI at first-line and maintenance therapy should be given priority for second-line therapy. For patients with negative EGFR gene-sensitive mutations, chemotherapy should be given priority.